Soleno TherapeuticsSLNO
SLNO
About: Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Employees: 92
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
312% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 17
138% more funds holding in top 10
Funds holding in top 10: 8 [Q4 2024] → 19 (+11) [Q1 2025]
70% more capital invested
Capital invested by funds: $2.29B [Q4 2024] → $3.9B (+$1.61B) [Q1 2025]
33% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 55
31% more funds holding
Funds holding: 165 [Q4 2024] → 216 (+51) [Q1 2025]
21% more call options, than puts
Call options by funds: $285M | Put options by funds: $236M
0.62% more ownership
Funds ownership: 118.37% [Q4 2024] → 118.99% (+0.62%) [Q1 2025]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$97
23%
upside
Avg. target
$112
41%
upside
High target
$145
83%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Debjit Chattopadhyay | 23%upside $97 | Buy Maintained | 8 May 2025 |
Baird Brian Skorney | 33%upside $105 | Outperform Maintained | 8 May 2025 |
Piper Sandler Yasmeen Rahimi | 83%upside $145 | Overweight Maintained | 24 Apr 2025 |
HC Wainwright & Co. Raghuram Selvaraju | 26%upside $100 | Buy Reiterated | 15 Apr 2025 |
Stifel James Condulis | 36%upside $108 | Buy Maintained | 28 Mar 2025 |
Financial journalist opinion
Based on 3 articles about SLNO published over the past 30 days
Neutral
Schaeffers Research
2 days ago
These 24 Stocks Are Ripe for a Short Squeeze
With the way negative stock market sentiment has piled up recently, short squeezes have generated some massive returns.
Neutral
GlobeNewsWire
3 weeks ago
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome
REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno's Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets (previously referred to as DCCR) for the treatment of adults and children four years and older with Prader-Willi syndrome (PWS) who have hyperphagia had been validated by the European Medicines Agency (EMA).
Neutral
GlobeNewsWire
3 weeks ago
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome
REDWOOD CITY, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced data presented from its clinical development program of VYKAT™ XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, at the Pediatric Endocrine Society (PES) Annual Meeting 2025, which was held May 15-18 in National Harbor, Maryland, USA. The presentation showed that resumption of VYKAT XR treatment in participants with PWS following a 16-week randomized withdrawal was associated with significant improvements in both hyperphagia and behavioral symptoms.
Neutral
Seeking Alpha
1 month ago
Soleno Therapeutics, Inc. (SLNO) Q1 2025 Earnings Call Transcript
Soleno Therapeutics, Inc. (NASDAQ:SLNO ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Anish Bhatnagar - Chief Executive Officer Meredith Manning - Chief Commercial Officer Jim Mackaness - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Debjit Chattopadhyay - Guggenheim Securities Kristen Kluska - Cantor Leland Gershell - Oppenheimer Brian Skorney - Baird James Condulis - Stifel Myriam Belghiti - LifeSci Capital Yale Jen - Laidlaw Operator Greetings, and welcome to the Soleno Therapeutics First Quarter 2025 Earnings Conference Call. At this time, note that all participants are in a listen-only mode.
Neutral
GlobeNewsWire
1 month ago
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results
REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the first quarter ended March 31, 2025.
Positive
Zacks Investment Research
1 month ago
Soleno Therapeutics (SLNO) is on the Move, Here's Why the Trend Could be Sustainable
Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Neutral
GlobeNewsWire
1 month ago
Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET
REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, May 7, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations.
Neutral
GlobeNewsWire
2 months ago
Soleno Therapeutics Announces VYKAT(TM) XR Launch
REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the U.S. commercial availability of VYKAT™ XR (diazoxide choline) extended-release tablets, the company's treatment for hyperphagia in patients four years of age and older with Prader-Willi syndrome (PWS), which was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025.
Positive
Zacks Investment Research
2 months ago
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.
Positive
Investors Business Daily
2 months ago
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher
Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech stock rocketed. The post Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher appeared first on Investor's Business Daily.
Charts implemented using Lightweight Charts™